ELIZABETH GOLDEN: Open Payments
NPI 1184811903 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,958 in 111 payments from 17 companies in 2025. Trend: 2023 $1,951 · 2024 $2,154 · 2025 $1,958
Food & beverage: $1,958
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 25 | $314 |
| PFIZER INC. | 21 | $256 |
| Amgen Inc. | 6 | $214 |
| ABBVIE INC. | 17 | $202 |
| Galderma Laboratories, L.P. | 5 | $157 |
| Arcutis Biotherapeutics, Inc. | 2 | $156 |
| UCB, Inc. | 10 | $152 |
| Lilly USA, LLC | 7 | $151 |
| Regeneron Healthcare Solutions, Inc. | 4 | $85 |
| GENZYME CORPORATION | 3 | $73 |
Products named: CIBINQO, OTEZLA, COSENTYX, DUPIXENT, Zoryve, Bimzelx, TALTZ, NEMLUVIO.
Industry payments across IN — which companies pay providers there.
